Reason for request

Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication

-


Clinical Benefit

Substantial

The actual benefit of Aromasin is substantial.


Clinical Added Value

moderate

According to the IES trial results, sequential therapy [tamoxifen followed by Aromasin (exemestane)] compared to tamoxifen provides a moderate improvement in actual benefit (IAB level III) in terms of efficacy when adjuvant hormone therapy is prescribed for 5 years to postmenopausal women with oestrogen receptor positive early breast cancer. Its prescription is therefore justified in patients who have received adjuvant therapy with tamoxifen for 2–3 years.


Contact Us

Évaluation des médicaments